Company Description
Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases.
Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma.
The company is also involved in the development of CNTY-308, a CD19-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 demonstrating preclinical efficacy comparable to autologous CD19 CAR-T cells for the treatment of B-cell mediated autoimmune diseases and malignancies; and CNTY-341, A CD19/CD22 dual-targeted CAR-iT cell therapy engineered with Allo-Evasion 5.0 which pairs dual targeting and primary T-cell-like functionality in an allogeneic cell with the goal of providing a differentiated therapy for B cell malignancies that are in preclinical trial.
In addition, it develops solid tumor CAR iT program exploiting Nectin-4 CAR and other validated targets, engineered with Allo-Evasion 5.0 and additional engineering aimed at overcoming the key barriers to success in solid tumors, as well as non-immune effector.
The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
| Country | United States |
| Founded | 2019 |
| IPO Date | Jun 18, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 150 |
| CEO | Brent Pfeiffenberger |
Contact Details
Address: 25 North 38th Street, 11th Floor Philadelphia, Pennsylvania 19104 United States | |
| Phone | 267 817 5790 |
| Website | centurytx.com |
Stock Details
| Ticker Symbol | IPSC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001850119 |
| CUSIP Number | 15673T100 |
| ISIN Number | US15673T1007 |
| Employer ID | 84-2040295 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Brent Pfeiffenberger M.B.A., Pharm.D. | Chief Executive Officer and Director |
| Dr. Adrienne Farid Ph.D. | Chief Development Officer, CCO and Head of Early Development |
| Dr. Gregory Russotti Ph.D. | Chief Technology and Manufacturing Officer |
| Dr. Morgan Conn Ph.D. | Chief Financial Officer |
| Dr. Chad A. Cowan Ph.D. | Chief Scientific Officer |
| Dr. Shane Williams Ph.D. | Chief People Officer |
| Michael Naso Ph.D. | Senior Vice President of Cell Engineering |
| Dr. Nick Trede M.D., Ph.D. | Senior Vice President and Head of Clinical Development |
| Katja Buhrer | SVice President, Head of Corporate Affairs and Strategy |
| Douglas Carr CPA | Senior Vice President of Finance and Operations and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | ARS | Filing |
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 19, 2025 | 8-K | Current Report |
| Mar 19, 2025 | 10-K | Annual Report |
| Mar 10, 2025 | 144 | Filing |
| Mar 10, 2025 | 144 | Filing |
| Mar 10, 2025 | 144 | Filing |
| Feb 28, 2025 | 8-K | Current Report |